Analytical Data
-
Gene name
PF4V1
- Application
-
Alternative Names
PF4V1;CXCL4V1;SCYB4V1;Platelet factor 4 variant
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10720
-
Expression Region
31-104aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSFARAEAE EDGDLQCLCV KTTSQVRPRH ITSLEVIKAG PHCPTAQLIA TLKNGRKICL DLQALLYKKI IKEHLES
-
Molecular Weight
11 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PF4V1, or platelet factor 4 variant 1, is a chemokine known for its role in modulating immune responses and promoting angiogenesis. Its significance has garnered increasing attention in recent years due to its implication in various pathophysiological conditions, including cancer, cardiovascular diseases, and inflammatory disorders. The study of PF4V1 recombinant protein offers insights into its biological functions and potential therapeutic applications. Researchers have focused on its ability to influence cell migration, attract immune cells, and stimulate the formation of new blood vessels, which are crucial processes in tumor growth and metastasis. Moreover, PF4V1's capacity to modulate the interactions between platelets and leukocytes is pivotal in understanding its role in thrombosis and inflammation. Advances in recombinant protein techniques have enabled the production of PF4V1 in substantial quantities, facilitating in vitro and in vivo studies. These investigations aim to elucidate the precise mechanisms underlying PF4V1's actions and its potential as a biomarker for disease prognosis or a target for innovative therapeutic strategies. As our understanding of PF4V1 expands, it may lead to impactful developments in treatments for various diseases where immune modulation and angiogenesis are critical factors.
